Form 4: Pyxis Oncology Director Jakob Dupont Acquires 38,741 Shares of Common Stock

Director Jakob Dupont acquired 38,741 shares of Pyxis Oncology common stock on March 26, 2024.

Summary

• On March 26, 2024, Jakob Dupont, a director of Pyxis Oncology, acquired 38,741 shares of common stock.
• The acquisition was made at a price of $0 per share.
• Following the transaction, Dupont directly owns 38,741 shares of Pyxis Oncology common stock.
• The acquired shares are in the form of restricted stock units that vest 100% on the first anniversary of the grant date, contingent upon continued service.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. The acquisition of shares by a director could be interpreted as a positive sign, but without further context, it's difficult to assign a strong positive sentiment.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The restricted stock units vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the transactions of company directors and officers.

Key Dates